FDA’s generic drug backlog has become increasingly popular recently, apparently to save money on user fees.
The agency is understood to be receiving a higher than normal number of submissions, which would be an effort to be in the review queue before the new application fees...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?